Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glenmark Pharmaceuticals reported its Q1 FY26 (quarter ended 30 June 2025) unaudited results. Consolidated revenue from operations was largely flat at Rs 3,264.4 crore vs Rs 3,244.2 crore a year ago, but net sales declined about 5% to Rs 3,059.3 crore from Rs 3,223.3 crore. Standalone revenue rose to Rs 2,394.9 crore from Rs 2,329.5 crore, though standalone net sales also slipped around 5% YoY. The company booked a one-time exceptional charge of Rs 323.2 crore (about US$37.75 million) to settle a US antitrust class-action lawsuit with the direct purchaser plaintiff group. This pulled consolidated profit after tax sharply down to Rs 47 crore from Rs 340.3 crore, while standalone PAT fell to Rs 330.2 crore from Rs 453.7 crore. Statutory auditor Suresh Surana & Associates LLP issued an unmodified limited review report.
The headline profit collapse is driven mainly by the one-time US legal settlement charge rather than core business deterioration, which may lead analysts to look through it to adjusted earnings. However, the 5% YoY drop in net sales is a mild concern, while the settlement removes a known legal overhang on the stock.